



June 30, 2026

To,
Listing/ Compliance Department
BSE LTD.
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

SCRIP CODE: 543748

Dear Sir/Madam,

To,
Listing/ Compliance Department
**National Stock Exchange of
India Limited**
“Exchange Plaza”, Plot No. C/1,
G Block, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
SYMBOL: AARTIPHARM

**Sub: Press Release by the Company
Ref: Regulation 30 of SEBI (LODR)
Regulations, 2015 (Listing Regulations’)**

Pursuant to Regulation 30 of Listing Regulations, please find enclosed Press Release dated June 30, 2026 titled "**Aarti Pharmalabs Limited inaugurates its new state-of-the-art additional manufacturing block at Tarapur Unit 5, Maharashtra to expand its production capacity**".

The Press Release is also available on the website of the Company i.e. www.aartipharmalabs.com

Please take the same on your records.

Thanking you,

Yours faithfully,
For AARTI PHARMALABS LIMITED

**JEEVAN MONDKAR
COMPANY SECRETARY AND LEGAL HEAD
ICSI M. NO. A22565**

Encl.: a/a.



Aarti Pharmalabs Limited inaugurates its new state-of-the-art additional manufacturing block at Tarapur Unit 5, Maharashtra to expand its production capacity

We are pleased to inform you that the company has inaugurated an additional manufacturing block located at Tarapur, MIDC, Plot No. L-28/29/99. The company has successfully obtained all the necessary permissions and approvals to start the facility. This block has a total capacity of 3600 TPA for Xanthine derivatives manufacturing, taking our total capacity to 9600 TPA, thereby placing us amongst top 3 Xanthine derivatives manufacturers globally.

Commenting on this milestone, **Mr. Rashesh Gogri, Chairman of Aarti Pharmalabs**, said:

“This is a significant milestone which represents a big leap forward for our company, expanding our production capabilities and strengthening our ability to serve our business partners. Trial production has been initiated, and the facility will be ramped up for optimum utilization in the next few quarters.”

The inauguration event witnessed the presence of the Senior Management team, alongside the dedicated members of the Aarti Pharmalabs team. This new manufacturing block emphasizes a commitment towards the company’s growth and capability development to cater to large customers’ needs.

About Aarti Pharmalabs Limited

Aarti Pharmalabs Limited (NSE: AARTIPHARM | BSE: 543748) is a prominent Indian pharmaceutical and nutraceutical manufacturer with a global presence. It focuses on innovation, sustainability, and is one of the leaders in the pharmaceutical and nutraceutical domain. The company specializes in offering comprehensive CDMO/CMO services for small molecule drug substances, catering to clinical and commercial phase projects for innovator pharma companies, with dedicated facilities for HPAPIs, corticosteroids, cytotoxic, and oncology products. It also offers generic APIs and Intermediates, and is globally amongst top producers of Xanthine derivatives.

Plant Location: Aarti Pharmalabs Limited, Unit-V, Plot L-28/29/99, Tarapur MIDC, Boisar, Maharashtra, India, Pin 401506.

AARTI PHARMALABS LIMITED

www.aartipharmalabs.com | CIN : L24100GJ2019PLC110964 | Email : info@aartipharmalabs.com

Admin Office : 204, Udyog Kshetra, 2nd Floor, Mulund - Goregaon Link Road, Mulund (W), Mumbai, PIN - 400 080, Maharashtra, INDIA, T : +91 22 67976666 | F : +91 22 25653234
Regd. Office : Plot No. 22-C/1 & 22-C/2, 1st Phase, G.I.D.C., Vapi 396 195, District - Valsad, Gujarat, INDIA, T : +91 260 2400467, +91 99099 94655